

Cell and Gene Therapy Tools, and Reagents: Global Markets

Market Research Report | 2024-11-07 | 136 pages | BCC Research

AVAILABLE LICENSES:

- Single User License \$4650.00
- 2-5 Users License \$5580.00
- Site License \$6696.00
- Enterprise License \$8035.00

Report description:

Description

Report Scope

This report analyzes the global market for cell and gene therapy tools and reagents. The market is segmented by product type, disease or application, end user and region. Product types include gene vectors, GMP proteins, GMP antibodies, GMP small molecules, bioreactors, multiplex immunoassays, immunoassays, leukapheresis, cell separation, cell expansion, cytokine release syndrome monitoring, cryopreservation reagents, and solutions and media. Diseases or applications include cancer and rare diseases. End users include pharmaceutical and biotech companies, academic research institutes, and clinical laboratories. The regions covered are North America, Europe, Asia-Pacific and the Rest of the World (RoW). For market estimates, data has been provided for 2023 as the base year, with forecasts for 2024 through 2029.

This report also examines strategies and collaborations, discusses the regulatory landscape, and analyzes macroeconomic factors when considering new technologies, the industry's increasing competitiveness, and emerging customer needs. This report also examines analytical frameworks, such as ESG analysis, patent analysis, competitive analysis, and strategic recommendations, which will aid companies in devising their strategic plans.

Report Includes

- 44 data tables and 57 additional tables
- An update on the global market for cell and gene therapy tools and reagents
- Analyses of the global market trends, with historic market revenue for 2021-2023, estimates for 2024, and projections of compound annual growth rates (CAGRs) through 2029
- A look at the market potential for the cell and gene therapy tools and reagents in the life sciences industry, market drivers, and forecasts for the market segments of product, application, end user and region
- Facts and figures pertaining to major market dynamics, product innovations, clinical trials, and government regulations
- Review of the prevalence of infectious disease, metabolic disorders and chronic ailments, along with the recent technological advances, competitive landscape, and the industry value chain

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- Coverage of the technological, economic and business considerations of the market, and the vendor landscape
- Analysis of the industry's regulatory framework and policies, and product pipeline
- Discussion of ESG challenges and ESG practices in the industry
- Market share analysis of the key companies in the industry and coverage of their proprietary technologies and strategies
- Company profiles of major players within the industry, including Thermo Fisher Scientific Inc., Sartorius CellGenix GmbH, and Miltenyi Biotec

Executive Summary

Summary:

Cell and gene therapy (CGT) is emerging as an essential tool for safeguarding human health. Techniques such as chimeric antigen receptor T-cell (CAR-T) therapy have emerged as ways to treat many cancers. The promise of gene therapy using technologies such as clustered regularly interspaced short palindromic repeats (CRISPR) is being realized in clinical trials. Therapies are being scaled up to treat lifethreatening The global CDMO market was valued at \$128 billion in 2023. The market is expected to grow at a compound annual growth rate (CAGR) of 7.0% to reach approximately \$191.6 billion by the end of 2029.

The CDMO sector is dynamic and offers service providers a wealth of opportunities for expansion. As the CDMO sector is trending toward consolidation, CDMO businesses are shifting focus to become one-stop shops or integrated pharmaceutical service providers.

With comprehensive services covering the whole drug development and manufacturing process, CDMOs are essential to the pharmaceutical industry. What distinguishes CDMOs from other service providers is this end-to-end support. A CDMO can offer services like pre-formulation and formulation development in the early phases of drug development. After the drug formulation is created, the CDMO can help with stability testing as well. A CDMO can supply clinical trial materials once the drug enters the clinical trial stage. These materials consist of the investigational medicinal product (IMP) that will be given to patients throughout the study and the paperwork required to comply with regulatory requirements. Ultimately, a CDMO can increase production from clinical trial quantities to commercial-scale quantities after the drug is approved for marketing. They can also manage the final product's packaging and delivery.

- Thermo Fisher Scientific Inc.

diseases such as cancer and rare gene-based diseases. As these therapies come to the fore, a new market for tools to develop these therapies using standard methodologies is emerging. CGT uses cells and genetic material to fight diseases. Cell therapy involves the transplantation of healthy human cells into a patient's body to replace or repair diseased or damaged tissue or cells. Gene therapy modifies a patient's genetic material. These are overlapping fields. Some products are developed using both cell and gene therapies. Tools and reagents are required to develop cell and gene therapies.

Table of Contents:

- Table of Contents
- Chapter 1 Executive Summary
- Market Outlook
- Scope of Report
- Market Summary
- Chapter 2 Market Overview
- Overview

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Technology Background: Cell Therapy
Types of Cell Therapy
Technology Background: Gene Therapy
Types of Gene Therapy
Approved CGT Products
Chapter 3 Market Dynamics
Market Dynamics
Market Drivers
Investments in CGT Research
Capacity Expansions for Clinical and Commercial Manufacturing
Increasing Incidence of Chronic Diseases
Collaborations and Acquisitions
Market Restraints
Complexity in Manufacturing and Supply Chain
Lack of Skilled Force
Market Opportunities
Harnessing the Advances in CGT Technologies
Regulatory Landscape
Gene Therapy Regulations
Cell Therapy Regulations
Viral and Non-Viral Vectors
Media
GMP Proteins and Antibodies
Leukapheresis
CGT Regulations in Europe
Chapter 4 Emerging Technologies and Developments
Closed and Automated Systems
Single-Use Technologies
Chapter 5 Market Segmentation Analysis
Market Trends
Segmentation Breakdown
Global Market for CGT Tools and Reagents, by Product
Immunoassays
Bioreactors
Leukapheresis
GMP Antibodies
Multiplex Immunoassays
Vectors
Cell Separation
Cryopreservation
Cell Expansion
Media
GMP Proteins
GMP Small Molecules
CRS Monitoring
Global Market for CGT Tools and Reagents, by Application
Cancer

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Rare Diseases
Other Diseases
Global Market for CGT Tools and Reagents, by End User
Pharmaceutical and Biotech Companies
Academic and Research Institutes
Clinical Laboratories
Geographic Breakdown
Global Market for CGT Tools and Reagents, by Region
North America
Europe
Asia-Pacific
Rest of the World
Chapter 6 Competitive Intelligence
Ranking of Leading Players
Strategies of Leading Companies
Product Launches
Collaborations and Partnerships
Expansions
Agreements
Acquisitions
Others
Chapter 7 Sustainability in the CGT Tool and Reagent Market: ESG Perspective
Introduction to ESG
ESG Performance in the Industry
ESG Practices in the CGT Tool and Reagent Industry
Environmental Performance
Concluding Remarks from BCC Research
Chapter 8 Appendix
Methodology
Abbreviations
References
Company Profiles
ABCAM LTD.
ADVERUM BIOTECHNOLOGIES INC.
AKRON BIOTECH
BIO-RAD LABORATORIES INC.
BIO-TECHNE
CYTIVA
FUJIFILM IRVINE SCIENTIFIC
MILTENYI BIOTEC
PROTEINTECH GROUP INC.
QIAGEN
REVVITY
SARTORIUS CELLGENIX GMBH
STEMCELL TECHNOLOGIES
THERMO FISHER SCIENTIFIC INC.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Cell and Gene Therapy Tools, and Reagents: Global Markets

Market Research Report | 2024-11-07 | 136 pages | BCC Research

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$4650.00
	2-5 Users License	\$5580.00
	Site License	\$6696.00
	Enterprise License	\$8035.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-03-05"/>
		Signature	

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

